Previous 10 | Next 10 |
2024-01-05 12:25:58 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotechnology company Allogene (NASDAQ: ALLO ) is certainly not having the day that many in the company’s C-Suite may have anticipated. Shares of ALLO stock are plunging yet ...
2024-01-05 10:00:03 ET More on Health Care Select Sector SPDR XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Covid-vaccine makers top laggard list, LLY and WST top gainers list Healthcare and uti...
2024-01-05 07:43:11 ET Allogene Therapeutics ( NASDAQ: ALLO ) fell ~22% premarket Friday after the cell therapy developer announced a pipeline shakeup that it said would cut costs and reduce cash burn. As part of the strategy named 2024 Platform Vision, the company will depr...
Partnership Will Utilize Foresight’s Ultra-Sensitive MRD Technology to Identify Patients for Enrollment in Allogene’s ALPHA3 Trial SAN FRANCISCO and BOULDER, Colo., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics Inc. (Nasdaq: ALLO), a clinical-stage biotechnology comp...
Four Core Programs Leverage Unique Attributes in Product Development and Trial Design to Demonstrate the Unmatched Potential of an Allogeneic CAR T Large B-Cell Lymphoma (LBCL) : Groundbreaking ALPHA3 Trial has Potential to Leapfrog Other CAR Ts and Embed Cemacabtagene Ansegedleucel (Cema...
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T ™ ) products for cancer, today announced that it will host a conference call to pr...
Comprehensive Review of All Patients in the Phase 1 ALPHA/ALPHA2 Trials Demonstrate that Adding Investigational ALLO-647 to Standard Lymphodepletion Can Yield Durable Responses and a Safety Profile Comparable to Approved Autologous CAR T Therapies Company Received Fast Track Designation for A...
SOUTH SAN FRANCISCO, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will participate in one upcoming invest...
2023-11-24 06:40:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips There are many ways to approach penny stocks , but one that has gained popularity in recent years focuses on stocks in this category that are prime candidates for a “short squeeze....
2023-11-03 13:17:21 ET More on Allogene Therapeutics Allogene Therapeutics, Inc. (ALLO) Q3 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Allogene Therapeutics Historical earnings data for Allogene Therapeutics Financial information for ...
News, Short Squeeze, Breakout and More Instantly...
Allogene Therapeutics Inc. Company Name:
ALLO Stock Symbol:
NASDAQ Market:
Allogene Therapeutics Inc. Website:
Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) rose sharply in today's pre-market trading after the company reported better-than-expect...
U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 20 points on Wednesday. Shares of DLocal Limited (NASDAQ:...
SOUTH SAN FRANCISCO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced the pricing of an underwr...